AI assistant
Hester Biosciences Ltd — Interim / Quarterly Report 2021
Jan 30, 2021
62222_rns_2021-01-30_6586365a-dcda-429b-8265-c5067265edec.pdf
Interim / Quarterly Report
Open in viewerOpens in your device viewer
Page 1 of 5
==> picture [521 x 96] intentionally omitted <==
Press Release
30 January 2021
Q3FY21 Sales up by 22%, 9MFY21 Sales up by 14%
Q3FY21 Net Profit up by 72%, 9MFY21 Net Profit up by 18%
Financial Highlights
| Financial Highlights | Financial Highlights | Financial Highlights | ||||
|---|---|---|---|---|---|---|
| INR in Million | ||||||
| Particulars | **Q3 ** | 9M | ||||
| FY21 | FY20 | Growth | FY21 | FY20 | Growth | |
| Net Sales | 528.18 | 433.93 | 22% | 1,453.19 | 1,279.94 | 14% |
| Net Profit | 132.91 | 77.30 | 72% | 310.42 | 262.21 | 18% |
| EPS(In INR) | 15.62 | 9.09 | 72% | 36.49 | 30.82 | 18% |
Division-wise sales in INR Million
| Particulars | **Q3 ** | **Q3 ** | **Q3 ** | 9M | 9M | 9M |
|---|---|---|---|---|---|---|
| FY21 | FY20 | Growth | FY21 | FY20 | Growth | |
| Poultry Healthcare | 396.09 | 300.24 | 32% | 1,037.77 | 904.61 | 15% |
| Animal Healthcare | 98.97 | 94.82 | 4% | 308.27 | 258.83 | 19% |
| Other | 33.12 | 38.87 | (15%) | 107.15 | 116.50 | (8%) |
| TOTAL | 528.18 | 433.93 | 22% | 1,453.19 | 1,279.94 | 14% |
Profitability Analysis
| Particular | Q3FY21 | Q3FY20 | 9MFY21 | 9MFY20 | FY20 |
|---|---|---|---|---|---|
| GP Margin | 68.22% | 66.76% | 64.04% | 67.37% | 66.97% |
| EBIDTA Margin | 38.97% | 29.97% | 35.35% | 33.17% | 31.12% |
| NP Margin | 25.16% | 17.81% | 21.36% | 20.49% | 18.43% |
| EPS in INRNon-Annualised | 15.62 | 9.09 | 36.49 | 30.82 | 36.70 |
Balance Sheet Analysis
| **Particular ** | Q3FY21 | Q3FY20 | Up/(Down) | 9MFY21 | 9MFY20 | Up/(Down) |
|---|---|---|---|---|---|---|
| ROE | 23.24% | 15.60% | 7.64% | 18.05% | 17.60% | 0.45% |
| ROCE | 26.66% | 17.82% | 8.84% | 22.65% | 19.84% | 2.81% |
| ROI | 18.55% | 11.11% | 7.44% | 14.41% | 12.53% | 1.88% |
Page 2 of 5
==> picture [521 x 96] intentionally omitted <==
| Business Overview of Hester India Analysing the performance through various parameters: |
Business Overview of Hester India Analysing the performance through various parameters: |
|---|---|
| 1. Poultry Healthcare Division |
It has registered a growth of 32% in Q3FY21 and 15% in 9MFY21 in comparison to the corresponding period last year. |
| 2. Animal Healthcare Division |
It has registered growth of 4% in Q3FY21 and 19% in 9MFY21. The seemingly low growth of 4% on a Q-to-Q basis is purely due to large tender orders received last year in Q3 as against not received this year in Q3. |
| 3. Vaccine sales | (poultry and animal divisions) have registered growth of 20% in Q3FY21 and 12% in 9MFY21 as compared to the corresponding period last year. |
| 4. Health product sales | (poultry and animal divisions) have registered growth of 48% in Q3FY21 and 31% in 9MFY21 as compared to the corresponding period last year. |
| 5. Geography | Domestic sales have registered a growth of 43% in Q3FY21 and 20% in 9MFY21 and the export sales have reduced by 51% in Q3FY21 and 5% in 9MFY21. While export orders have continued to pour in, the higher demand within India compelled us to divert the production for domestic sales. |
| 6. Brucella tender | The outcome of the tender for Brucella vaccine under the National Animal Disease Control Program of the Government of India is awaited. Sales through this tender are expected to commence from March 2021. |
| 7. Bird Flu impact | There has been no impact on our sales due to the current Bird Flu situation in India. |
Going further:
-
Hester is set to launch a new range of Herbal Health products in this quarter.
-
Vaccine production expansion plans have been finalised for India. We hope to embark on the expansion activities in this quarter, the details would be shared in the next few weeks.
-
In view of the various vaccine opportunities within India, including those of Brucella and LSD vaccines, till our expansion activities go on-stream, temporarily, Hester will focus on the Indian market. Exports will be mainly of health products.
-
Hester is also evaluating expansion opportunities in manufacturing and distribution of Animal Health Products and Biologicals, worldwide.
-
The Board has authorised the management to explore appropriate financing alternatives for the expansion activities for an aggregate outlay of INR 2 billion.
-
Our developmental activities are ongoing for the human Covid-19 vaccine with IIT Guwahati.
Business Overview of Hester Nepal
-
Revenue for Q3FY21 was recorded at INR 36.20 Mn as against INR 8.69 Mn in Q3FY20.
-
Revenue for 9MFY21 was recorded at INR 43.33 Mn as against INR 45.36 Mn in 9MFY20.
Q3FY21 has performed as per expectations. FAO Tenders for PPR have now started, (though in a small way), which has resulted in increase in top-line in Q3FY21 and we are expecting the same to follow in the coming part of the year.
Financials in INR Million
| Particular | Q3FY21 | Q3FY20 | 9MFY21 | 9MFY20 | FY20 |
|---|---|---|---|---|---|
| Net Sales | 36.20 | 8.69 | 43.33 | 45.36 | 161.80 |
| Net Profit/ (Loss) | 9.41 | 6.54 | (16.54) | (18.36) | 39.39 |
Page 3 of 5
==> picture [521 x 96] intentionally omitted <==
Business Overview of Texas Lifesciences
-
Revenue for Q3FY21 was recorded at INR 51.69 Mn as against INR 33.31 Mn in Q3FY20.
-
Revenue for 9MFY21 was recorded at INR 113.07 Mn as against INR 93.09 Mn in 9MFY20.
Texas Lifesciences has continued to show growth in topline due to the growth in sales of health products at Hester.
The company has also started direct registration process for products to be exported to various African countries.
Financials in INR Million
| Particular | Q3FY21 | Q3FY20 | 9MFY21 | 9MFY20 | FY20 |
|---|---|---|---|---|---|
| Net Sales | 51.69 | 33.31 | 113.07 | 93.09 | 128.03 |
| Net Profit/ (Loss) | 4.44 | 4.70 | 9.70 | 9.99 | 10.17 |
Business Overview of Hester Tanzania
-
Revenue for Q3FY21 was recorded at INR 16.61 Mn as against INR 8.87 Mn in Q3FY20.
-
Revenue for 9MFY21 was recorded at INR 32.18 Mn as against INR 20.86 Mn in 9MFY20.
Company is in process of establishing sales and distribution network keeping in focus the Demands from domestic market as well as East African countries
Financials in INR Million
| Particular | Q3FY21 | Q3FY20 | 9MFY21 | 9MFY20 | FY20 |
|---|---|---|---|---|---|
| Net Sales | 16.61 | 8.87 | 32.18 | 20.86 | 27.03 |
| Net Profit/ (Loss) | 8.86 | 8.22 | 0.47 | 13.35 | (2.68) |
Business Overview of Hester Africa
The project is near completion. Commercial production has been slated for June 2021.
==> picture [53 x 55] intentionally omitted <==
Rajiv Gandhi Hester Biosciences Limited CEO Managing Director
Page 4 of 5
Hester India:
==> picture [451 x 254] intentionally omitted <==
Hester Nepal:
==> picture [451 x 302] intentionally omitted <==
Page 5 of 5
==> picture [72 x 9] intentionally omitted <==
----- Start of picture text -----
Hester Africa:
----- End of picture text -----
==> picture [451 x 254] intentionally omitted <==
==> picture [91 x 88] intentionally omitted <==
Better health for human beings through healthier animals